**Checklist for Reporting Human Islet Preparations Used in Research**

Adapted from Hart NJ, Powers AC (2018) Progress, challenges, and suggestions for using human islets to understand islet biology and human diabetes. Diabetologia <https://doi.org/10.1007/s00125-018-4772-2>.

|  |  |
| --- | --- |
|  | |
| **Manuscript DOI:** https://doi.org/10.233/DB22-0117 **(**Example, https://doi.org/10.2337/db18-1234) | |
| **Title:** Stem Cell therapy Improve Human Islet Graft Survival in Mice via Regulation of Macrophages | |
| **Author list:** Wenyu Gou, Wei Hua, Lindsay Swaby, Wanxing Cui, Erica Green, Katherine Morgan, Charlie Strange, Hongjun Wang | |
| **Corresponding author: Hongjun Wang** | **Email address:** [wangho@musc.edu](mailto:wangho@musc.edu) |

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Islet preparation** | **1** | **2** | **3** | **4** | **5** | **6** | **7** | **8a** |
| **MANDATORY INFORMATION** | | | | | | | | |
| Unique identifier | HP20199 | HP20209 | HP20288 | HP21217 | HP22012 | HP22067 |  |  |
| Donor age (years) | 46 | 60 | 56 | 58 | 51 | 36 |  |  |
| Donor sex (M/F) | F | F | M | M | F | M |  |  |
| Donor BMI (kg/m2) | 38.062 | 36.865 | 26.133 | 27.398 | 36.546 | 51.268 |  |  |
| Donor HbA1c or other measure of blood glucose control | 5.5% | 5.0% | 5.6% | 5.5% | 5.1% | 5.5% |  |  |
| Origin/source of isletsb | MedStar Georgetown University Hospital (MGUH) | MedStar Georgetown University Hospital | MedStar Georgetown University Hospital | MedStar Georgetown University Hospital | MedStar Georgetown University Hospital | MedStar Georgetown University Hospital |  |  |
| Islet isolation centre | MGUH, Islet Cell Lab | MGUH, Islet Cell Lab | MGUH, Islet Cell Lab | MGUH, Islet Cell Lab | MGUH, Islet Cell Lab | MGUH, Islet Cell Lab |  |  |
| Donor history of diabetes? Yes/No | No | No | No | No | No | No |  |  |
| **If Yes, complete the next two lines if this information is available** | | | | | | | | |
| Diabetes duration (years) |  |  |  |  |  |  |  |  |
| Glucose-lowering therapy at time of deathc |  |  |  |  |  |  |  |  |

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **RECOMMENDED INFORMATION** | | | | | | | | |
| Donor cause of death | Anoxia | Cerebrovascular  /Stroke | Anoxia | Cerebrovascular  /Stroke | Cerebrovascular  /Stroke | Cerebrovascular  /Stroke |  |  |
| Warm ischaemia time (h) | 0.75 | 0 | 0.28 | 0 | 0 | 0 |  |  |
| Cold ischaemia time (h) | 15.05 | 3.9 | 3.35 | 17.92 | 10.92 | 11.67 |  |  |
| Estimated purity (%) | 90 | 90 | 90 | 90 | 90 | 90 |  |  |
| Estimated viability (%) | 92.14 | 83.7 | 99.0 | 95 | 90 | 90 |  |  |
| Total culture time (h)d | 24 | 24 | 24 | 24 | 24 | 24 |  |  |
| Glucose-stimulated insulin secretion or other functional measuremente | N/A | N/A | N/A | N/A | N/A | N/A |  |  |
| Handpicked to purity? Yes/No | No | No | No | No | No | No |  |  |
| Additional notes |  |  |  |  |  |  |  |  |

aIf you have used more than eight islet preparations, please complete additional forms as necessary

bFor example, IIDP, ECIT, Alberta IsletCore

cPlease specify the therapy/therapies

dTime of islet culture at the isolation centre, during shipment and at the receiving laboratory

ePlease specify the test and the results